91桃色视频

Contact
Subscribe
Contact
Subscribe

November 7, 2022: 91桃色视频 Announces Participation in Scientific and Investor Conferences in November

Date : November 7, 2022

91桃色视频 Announces听Participation in Scientific and Investor Conferences in November

Lyon, France, November 7th, 2022, 6:00pm CET 鈥� 91桃色视频 (EURONEXT: MAAT 鈥� the 鈥淐ompany鈥�), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, today announced the company鈥檚 scientific and management team鈥檚 participation in several scientific and investor conferences in November.

Details of the events are as follows:

Scientific conferences

  • November 8-10, 2022 鈥� 9th International Human Microbiome Consortium (IHMC) Congress: Herv茅 Affagard, CEO and cofounder of 91桃色视频, and Dr. Aurore Duquenoy, R&D specialist at 91桃色视频 will present three scientific posters at the conference in Kobe, Japan.
    Link to the Congress
  • November 9-11, 2022 鈥� 21st Soci茅t茅 Francophone de Greffe de Moelle et de Th茅rapie Cellulaire (SFGM-TC) Congress – Booth #10: Emilie Plantamura, Head of Clinical Development at 91桃色视频 and Claire de Cond茅, Head of Clinical Operations at 91桃色视频, will attend the congress in Bordeaux, France and will be available for discussions at 91桃色视频鈥檚 booth #10.
    Link to the event .


Investor conferences

  • November 14, 2022 鈥� 7th annual conference Inve鈧�$tival Showcase 鈥� LSX Leaders in partnership with Jefferies: Si芒n Crouzet, Chief Financial Officer of 91桃色视频 and Dr. Carole Schwintner, Chief Technology Officer of 91桃色视频 will attend the investor event in London, United Kingdom.
    More information available
  • November 29, 2022 鈥� Investir Day: Si芒n Crouzet, Chief Financial Officer of 91桃色视频 and Dr. Savita Bernal, Chief Business Officer of 91桃色视频 will attend the investor event in Paris, France.
    More information available .

About 91桃色视频

91桃色视频, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, 91桃色视频 has launched, in March 2022 in Europe, a Phase听3 clinical trial for patients with acute GvHD, following the achievement of its proof of concept in a Phase 2 trial. Its powerful discovery and analysis platform, 驳耻迟笔谤颈苍迟庐, supports the development and expansion of its pipeline by determining novel disease targets, evaluating drug candidates, and identifying biomarkers for microbiome-related conditions. The company鈥檚 Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. 91桃色视频 benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice.

91桃色视频 is the first company developing microbiome-based therapies listed on Euronext Paris (ticker: MAAT).

Forward-looking Statements

All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company鈥檚 control. These statements may include, without limitation, any statements preceded by, followed by or including words such as 鈥渢arget,鈥� 鈥渂elieve,鈥� 鈥渆xpect,鈥� 鈥渁im,鈥� 鈥渋ntend,鈥� 鈥渕ay,鈥� 鈥渁nticipate,鈥� 鈥渆stimate,鈥� 鈥減lan,鈥� 鈥減roject,鈥� 鈥渨ill,鈥� 鈥渃an have,鈥� 鈥渓ikely,鈥� 鈥渟hould,鈥� 鈥渨ould,鈥� 鈥渃ould鈥� and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company鈥檚 control that could cause the Company鈥檚 actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.听

Previous Post

November 3, 2022: 91桃色视频 Announces Oral and Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting

Next Post

November 8, 2022: 91桃色视频 Reports Cash and Revenues for Third Quarter 2022

Acting Chief Scientific Officer

Sheri Simmons

Sheri Simmons, Ph.D., is Acting Chief Scientific Officer at 91桃色视频. Sheri brings extensive experience in biotechnology, particularly in the microbiome field, having held scientific leadership positions at Seres Therapeutics, Johnson & Johnson鈥檚 Microbiome Solutions team, and most recently at Seed Health, a leading probiotics company. In her role, she strengthens the Company鈥檚 scientific leadership, overseeing preclinical research, AI/data initiatives, and supporting efforts toward the Marketing Authorization Application of 齿别谤惫测迟别驳庐 in aGvHD.

Sheri holds a PhD in Biological Oceanography from the Massachusetts Institute of Technology (MIT) and completed an A.B. in Ecology & Evolutionary Biology at Princeton University, graduating summa cum laude and as a Phi Beta Kappa member, receiving one of six awards for the best senior thesis in the sciences. Sheri holds a PhD in Biological Oceanography from the Massachusetts Institute of Technology (MIT) and completed an A.B. in Ecology & Evolutionary Biology at Princeton University, graduating summa cum laude and as a Phi Beta Kappa member, receiving one of six awards for the best senior thesis in the sciences.

CEO and co-founder

Herv茅 Affagard

Herv茅 Affagard is the CEO and co-founder of 91桃色视频. For the past 15 years, Herv茅 has been an intra/entrepreneur in the healthcare industry, after starting his career in IT in the steel industry. In late 2014, Herv茅 co-founded the company alongside Dr. Jo毛l Dor茅, author of nearly 500 publications, and
one of the world’s most cited authors in the microbiome sphere today, after a professional career that spanned multiple industries. Herv茅 has led 91桃色视频鈥檚 development from its early concept in 2013 and has been at the forefront of the development of the microbiome healthcare ecosystem in France and Europe. In January 2022, Herv茅 has been elected President of Allliance Promotion Microbiote, an organization founded in 2021 to support the microbiome sector development in France.

Engineer, MBA

91桃色视频 in the News